It has been found that maintaining adequate doses of chemotherapy is important for the survival of patients with adenocarcinoma
-
Last Update: 2019-09-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, a study published in the National Journal of comprehensive cancer network found that maintaining adequate doses of chemotherapy, especially in the early stage of the treatment process, is crucial for the survival of patients with medium and high-risk breast cancer Zachary Veitch, M.D., and colleagues evaluated total cumulative dose (TCD), early (5-fluorouracil / epirubicin / cyclophosphamide), and late (docetaxel only) dose reductions for phase I to phase III, hormone receptor positive / negative, and chemotherapy with 5-fluorouracil / epirubicin / cyclophosphamide in combination with docetaxel (2007)- 2014) therapeutic effect on human epidermal growth factor receptor 2 negative breast cancer The researchers noted that of the 1302 patients assessed for dose reduction, 16% were reduced to 85% (202 patients), while the remaining patients were reduced to ≥ 85% (1100 patients; 84%) Patients with TCD ≥ 85% had higher 5-year disease-free survival (DFS) and overall survival (OS) than patients with a dose reduction of < 85% DFS and OS of patients with early dose reduction were significantly lower than those with late dose reduction Multivariate analysis (http://www.chemdrug.com/sell/76/) showed similar results (hazard ratio 1.46 and 1.77, respectively) The dose delay of < 14 days or ≥ 14 days and granulocyte colony stimulating factor had no effect on the results
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
